جستجوی استاد راهنمای دانشگاهی

• Lipid Metabolism
• Cachexia
• Adipose Tissue
• +۵ مورد دیگر

Dr. Maria Rohm serves as Head of the Research Division 'Tissue Crosstalk' at the Institute for Diabetes and Cancer, Helmholtz Munich, leading investigations into metabolic disease interconnections since 2020. Previously a Junior Group Leader (2017-2020), her career includes postdoctoral research at the University of Oxford (2014-2017) under a Novo Nordisk Fellowship and the German Cancer Research Center (2012-2014). Her educational foundation comprises Biology studies at Heidelberg University and the University of Manchester, culminating in a Dr. rer. nat. from Heidelberg in 2012 where she examined adipose tissue lipolysis in obesity. Rohm's research centers on tissue crosstalk mechanisms in diabetes, metabolic syndrome, and cancer cachexia, emphasizing lipid/glucose metabolism and adipose tissue function. She pioneers the conceptual framework that obesity/diabetes and cachexia represent opposing metabolic extremes requiring integrated study, with particular focus on ceramide signaling, mitochondrial dysfunction, and energy homeostasis disruptions in disease pathogenesis. Her multi-omics approach reveals critical overlaps in disease pathways that could transform therapeutic development. Publication analysis shows consistent focus on metabolic reprogramming across cancer cachexia and diabetes, with emerging emphasis on lipid mediators as biomarkers and therapeutic targets. Key trends include translational exploration of AMPK-stabilizing peptides and ceramide modifications for treating tissue wasting. Her scientific recognition includes: Vincenz-Czerny Price for Oncology (2021) ERC Starting Grant (2020) Lipidology Prize (2019) Research Award by German Diabetes Society (2013) Rohm directs significant grant-funded research, notably the ERC Starting Grant investigating metabolic crosstalk in cachexia. As Board of Directors and Educational Committee member of the Cancer Cachexia Society, she drives global research initiatives for this fatal condition affecting most cancer patients. Her advocacy highlights the urgent need for mechanistic understanding to develop effective treatments. She leads the 'Tissue Crosstalk in Cancer Metabolism' research group at Helmholtz Munich, employing multi-omics and mouse models to dissect metabolic communication between organs. Her team collaborates extensively within European research networks, with emphasis on translating basic discoveries into clinical applications for metabolic diseases and cancer-associated wasting syndromes.

Mauricio Berriel Diazمشاهده پروفایل

پژوهشگر

• Energy Metabolism
• Cancer Cachexia
• Tumor Metabolism
• +۳ مورد دیگر

Mauricio Berriel Diaz is a Researcher at the Helmholtz Center Munich , serving as Deputy Director and Head of the Division Metabolism and Cancer since 2015. His work bridges energy metabolism and oncology, with a focus on systemic metabolic interactions in cancer progression and therapy. Deputy Director, Institute for Diabetes & Cancer (since 2015) Head of Division Metabolism and Cancer Research Interests: His research program investigates the interconnections between energy metabolism and cancer, particularly: Mechanisms of cancer cachexia (systemic wasting syndrome) Tumor-host metabolic interactions Lipid metabolism in obesity-related cancer progression Therapeutic targeting of tumor metabolism Systemic metabolic regulation in disease contexts Scientific Contributions: His work has expanded understanding of cancer cachexia beyond skeletal muscle loss to include roles of liver and adipose tissue metabolism, with recent publications in Journal of Cachexia, Sarcopenia and Muscle , EMBO Molecular Medicine , and Cell Metabolism . Scientific Leadership: Selected honors and editorial roles include: Associate Editor, Journal of Cachexia, Sarcopenia and Muscle (since 2018) Peer reviewer for top journals including Nature Communications and Oncogene Referee for Swiss National Science Foundation Sinergia Program (2015)

• Neuroendocrinology
• Neuroendocrine Tumors
• Translational Cancer Research
• +۴ مورد دیگر

Prof. Dr. Natalia S. Pellegata serves as Head of the Neuroendocrinology Division at the Institute for Diabetes and Cancer, Helmholtz Munich since 2016 and holds an Adjunct Professorship at the Technical University of Munich's Faculty of Medicine since 2018. With over two decades of research experience, she leads translational studies focused on neuroendocrine tumors (NETs) and cancer cachexia, leveraging unique animal models for drug discovery. Her seminal work established CDKN1B as a tumor susceptibility gene, defining MEN4 syndrome in humans through cross-species validation using the MENX rat model. Current research identifies druggable pathways including BMP signaling in pheochromocytomas and angiopoietin/Tie2 in pituitary tumors, providing clinical rationale for dual PI3K/mTOR inhibitors and anti-angiogenic therapies. Recent investigations extend into metabolic dysregulation in cancer cachexia, emphasizing lipid metabolism alterations. Publication analysis reveals consistent focus on metabolic mechanisms in tumor progression, with recurring themes in lipid metabolism (ceramides, PLA2G7), stress response pathways, and metabolic enzyme targeting across neuroendocrine and breast cancers. These studies bridge preclinical models with human pathophysiology through rigorous translational frameworks. Scientific recognition includes: Eleonore Trefftz Visiting Professorship for Women Scientists, Technical University of Dresden (2015) Her laboratory operates within major collaborative networks including CRC/TRR 205 'Adrenal Research', the European Neuroendocrine Tumor Society (ENS@T), and legacy SFB824 imaging consortia, utilizing functional imaging for in vivo therapy monitoring and preclinical drug evaluation.

• Protein Interaction Networks
• Microbe-Host Interactions
• Systems Biology
• +۴ مورد دیگر

Prof. Dr. Pascal Falter-Braun is a pioneering academic in network biology, serving as Director of the Institute for Network Biology at Helmholtz Munich and Chairholder for Microbe-Host Interactions at LMU Munich. His work focuses on mapping and analyzing protein interaction networks to understand disease mechanisms and develop therapeutic strategies. Research Interests: Decoding how biochemical networks interpret genetic information into phenotypes Investigating microbe-host interactions in obesity-related metabolic disorders and cancer cachexia Applying AI/Deep Learning for pharmacological intervention discovery Systematic mapping of molecular interactions via high-throughput robotics Integrating population genetics with network analysis for disease prevention Developing mechanistic validation pipelines for network predictions Scientific Achievements: ERC Consolidator Grant recipient (2015) Leader in SARS-CoV-2 contactome mapping Established foundational frameworks for multi-layer network analysis Created high-throughput pipelines for protein interaction studies Key contributor to phytohormone network understanding His interdisciplinary approach combines experimental biology, bioinformatics, and machine learning to identify genetic vulnerabilities and pharmacological targets. The institute’s work spans from basic network principles to translational applications for complex diseases.

Oliver Plettenburgمشاهده پروفایل

استاد

• Medicinal Chemistry
• Drug Discovery
• Organic Chemistry
• +۳ مورد دیگر

Prof. Oliver Plettenburg holds a Professorship at the Institute of Organic Chemistry within the Faculty of Natural Sciences at Leibniz University Hannover. His primary research focuses on medicinal chemistry, drug discovery, and nanotechnology applications in biomedical contexts. He is affiliated with the Medicinal Chemistry Group and contributes to the Examination Board for Chemistry (B.Sc./M.Sc.). His research interests span drug design targeting metabolic disorders, cancer therapies, and molecular imaging technologies. Notable projects include developing optoacoustic imaging agents, peptide-based drugs for cachexia, and inhibitors of protein-protein interactions for parasitic diseases. His work frequently integrates organic synthesis with biological applications, such as enzyme electrode fabrication and nanoparticle therapy. Prof. Plettenburg has co-authored over 70 publications since 1999, including high-impact studies in Nature Metabolism , Journal of Medicinal Chemistry , and ACS Applied Materials & Interfaces . His lab collaborates extensively with institutions in Germany and internationally, focusing on translating chemical innovations into clinical applications. Awards and recognitions are not explicitly listed in the provided texts, though his sustained contributions to drug discovery research indicate significant academic impact. His group actively engages in interdisciplinary projects bridging organic chemistry, pharmacology, and biomedical engineering.

Hana Algülمشاهده پروفایل

استاد

• Pancreatic Cancer
• Tumor Metabolism
• Cancer Immunology
• +۳ مورد دیگر

Prof. Hana Algül is a Professor at the Technical University of Munich (TUM), leading the Chair of Tumor Metabolism within the TUM School of Medicine and Health. She holds a dual background in clinical medicine and scientific research, having earned degrees from the University of Ulm and the University of California Davis. Since 2003, she has served as a Clinician Scientist at TUM's Klinikum rechts der Isar, focusing on pancreatic cancer mechanisms and translational research. Her academic career includes key roles in clinical trials (e.g., NEONAX) and drug development. Her research emphasizes tumor metabolism's role in pancreatic cancer progression, particularly autophagy regulation, immune-tumor interactions, and cachexia pathways. She investigates carcinogenesis triggers and immune modulation strategies, aiming to identify novel therapeutic targets. Notable contributions include studies on KRAS-driven cancers, biomarker discovery via imaging, and the impact of clinical trials during pandemics. Prof. Algül’s work integrates preclinical models (mouse studies) with clinical data, addressing both molecular mechanisms and patient outcomes. Her team explores synergistic drug combinations (e.g., SHP2/ERK inhibition) and biomarkers for personalized treatment. She has published extensively on pancreatic cancer subtypes, metastasis pathways, and the effects of systemic therapies like olaparib in BRCA-mutated cancers. Education: MD from University of Ulm, Postdoctoral work at University of California Davis Labs/Teams: TUM Cancer Center, Klinikum rechts der Isar Research Group Key Projects: NEONAX trial (perioperative chemotherapy), POLO trial (olaparib maintenance), Hourglass subtyping framework

Sebastian Theurichمشاهده پروفایل

دانشیار

• Cancer Metabolism
• Immunometabolism
• Hematology
• +۹ مورد دیگر

Professor Sebastian Theurich serves as Associate Professor for Cancer- and Immunometabolism at the Department of Medicine III, LMU University Hospital in Munich, Germany. He also holds positions as Attending Physician, Head of the Multiple Myeloma Program, and Head of the Interdisciplinary Oncologic Outpatient Unit at Campus Innenstadt. Since 2019, he has led the Cancer- and Immunometabolism Research Group at the Gene Center LMU, bridging laboratory research with clinical oncology practice. Dr. Theurich completed his medical education at the Universities of Lübeck, Berlin, and Umea (Sweden) from 1997 to 2004, including a clinical fellowship at Columbia University. He earned his MD with distinction from the Max-Delbrück-Center for Molecular Medicine and Charité, Humboldt-University Berlin in 2006, completed board certification in Internal Medicine, Hematology, and Oncology in 2012, and received his habilitation from the University of Cologne in 2015 under Professor Michael Hallek's mentorship. His research focuses on how metabolic processes influence immune responses in cancer, particularly examining how body composition, adipose tissue distribution, and nutritional status impact cancer progression and treatment responses. His laboratory has made significant contributions to understanding the connections between obesity, insulin resistance, and cancer development through studies on natural killer cells and immunometabolic host factors. Dr. Theurich's work demonstrates how visceral fat distribution affects cytokine release syndrome severity after CAR-T therapy and how metabolic parameters influence responses to immune checkpoint inhibitors. His publication record reveals a strong focus on translating basic immunometabolism findings into clinical applications, with recent articles examining CAR T-cell therapy optimization, bispecific antibodies for multiple myeloma, and the impact of steroid hormones on anti-tumor immunity. His research spans from molecular mechanisms of T-cell exhaustion to large-scale clinical studies evaluating real-world treatment outcomes. Dr. Theurich has received recognition including the Basic Science Research Award from the Glaxo-Smith-Kline Foundation (2018) and is a Researcher of the German Cancer Consortium (DKTK) since 2019. He serves on the editorial board of "Immunometabolism" and has contributed to clinical guidelines for therapies including mogamulizumab. His work on nutrition care in cancer and implementation of exercise therapy demonstrates his commitment to comprehensive patient-centered oncology care. As a clinician-scientist, Dr. Theurich actively supervises research projects and collaborates with numerous institutions across Germany and internationally. His laboratory investigates novel approaches to enhance cancer immunotherapy through metabolic pathway modulation, with potential applications for personalizing cancer treatment based on patients' metabolic and immunological profiles.

Tienush Rassafمشاهده پروفایل

استاد

• Cardio-Oncology
• Myocardial Ischemia-Reperfusion Syndrome
• Cardiac Toxicity of Cancer Therapies
• +۳ مورد دیگر

Prof. Dr. Tienush Rassaf is the Director of the Clinic for Cardiology and Vascular Medicine at the University Hospital Essen, affiliated with the University of Duisburg-Essen's Medical Faculty. His research focuses on cardio-oncology, myocardial ischemia-reperfusion injury, and cardiac toxicity from cancer therapies. He leads studies on heart failure management, mechanical circulatory support, and hypoxic vasodilation mechanisms. Recent work includes clinical trials on iron deficiency treatment in heart failure (FAIR-HF2) and immune therapy-induced cardiotoxicity. He contributes to ESC guidelines and collaborates internationally in cardio-oncology and critical care. Key publications (2023–2025) address cardiogenic shock outcomes, transcatheter valve interventions, and biomarker-driven risk stratification in cancer patients. His work is funded by DFG, EFRE, and industry grants, advancing translational research at the West German Heart and Vascular Center.

• Palliative Care
• Pain Management
• Symptom Assessment
• +۴ مورد دیگر

Prof. Dr. Lukas Radbruch is a Professor at the Department of Palliative Medicine, University Hospital Bonn, affiliated with the Medical Faculty of the University of Bonn. He serves as President of the German Association for Palliative Medicine and the International Association of Hospice and Palliative Care. His research focuses on symptom assessment, opioid treatment, ethical issues in palliative care, and global health policy. He has authored key publications on redefining palliative care and its role during the COVID-19 pandemic. Affiliations: Klinik für Palliativmedizin (University Hospital Bonn), Leopoldina National Academy of Science Editorial Roles: Editor of 'Der Schmerz' Research interests include palliative care ethics, pain management, and global health initiatives. His work has been funded by the European Commission, German Research Foundation (DFG), and German Cancer Aid. He co-authored the German palliative care textbook and led the Lancet Commission on Palliative Care (2015–2017).

• Nephrology
• Medical Imaging
• Oncology
• +۵ مورد دیگر

Dominik Kylies is an academic physician-scientist at the University Medical Center Hamburg-Eppendorf, affiliated with the Faculty of Medicine and Department of Nephrology. His research spans multiple disciplines including nephrology, oncology, and medical imaging, with a particular focus on kidney diseases, cancer-related complications, and advanced diagnostic techniques. As evidenced by his publication record, Dr. Kylies collaborates extensively with researchers across multiple institutions and contributes significantly to translational medical research. Dr. Kylies' research interests primarily center on nephrology with specific focus areas including membranous nephropathy, complement system activation, kidney organoid modeling, and the intersection of kidney disease with cancer. His work also extends to sarcopenia and body composition analysis in cancer patients, particularly examining how muscle wasting affects outcomes in multiple myeloma and osteosarcoma. Additionally, he investigates the role of the microbiome in cancer treatment efficacy and explores advanced imaging techniques for pathology specimen analysis. Analysis of Dr. Kylies' publication trends reveals a strong focus on translational research bridging basic science and clinical applications. His work spans kidney disease mechanisms, cancer complications, and advanced diagnostic methodologies. Recent publications demonstrate increasing sophistication in multi-omics approaches, spatial biology techniques, and super-resolution imaging. The research shows particular strength in connecting molecular mechanisms (like complement activation or microbiome metabolites) with clinical outcomes in nephrology and oncology. Dr. Kylies has contributed to significant advancements in understanding kidney disease mechanisms, particularly regarding complement system activation in membranous nephropathy and the role of collagen IV modifications in thin basement membrane disease. His work on sarcopenia in cancer patients has provided important clinical insights for risk stratification in stem cell transplantation. The development of optimized protocols for multiomics processing of kidney tissue represents a technical advancement in the field. Dr. Kylies collaborates with major research groups including the Center for Inflammation, Infection and Immunity (C3i) and the University Cancer Center Hamburg (UCCH). His research appears to be supported by institutional resources at the University Medical Center Hamburg-Eppendorf, including access to Core Facilities and the Research Information System. His extensive publication record suggests involvement in multiple collaborative research projects across nephrology, oncology, and immunology domains. Dr. Kylies is affiliated with the Third Medical Clinic and Polyclinic at UKE, which houses specialized research facilities for nephrology and internal medicine. His work appears connected to multiple research networks including the Cardiovascular Research Center (CVRC) and the Center for Health Care Research & Public Health. The collaborative nature of his publications suggests active participation in interdisciplinary research teams focused on kidney disease mechanisms and cancer-related complications.

• genetics
• diabetes
• phenotyping
• +۵ مورد دیگر

Martin Hrabě de Angelis is a Research Director at Helmholtz Munich and Full Professor and Chair of Experimental Genetics at Technical University Munich. He serves as Director of the Institute of Experimental Genetics at Helmholtz Munich and chairs the European research consortium INFRAFRONTIER ERIC. Positions: Research Director (since 2020), Full Professor (since 2003), Director of Institute of Experimental Genetics (since 2000) Key Affiliations: German Center for Diabetes Research (DZD), International Mouse Phenotyping Consortium (IMPC), INFRAFRONTIER Ltd. His research focuses on genetics, diabetes, phenotyping, epigenetics, and large-scale functional genomics , with notable work on ENU-mutagenesis screens and epigenetic inheritance of metabolic diseases. Recent publications highlight his contributions to understanding: Genetic underpinnings of cancer cachexia and ocular diseases Novel gene therapies for rare metabolic disorders Sex-based differences in exercise physiology Chemoproteomic approaches to drug discovery He has received prestigious honors including the Paul Langerhans Medal (2021), IMPC Award of Excellence (2019), and multiple honorary doctorates (2018-2017). As co-founder of the German Center for Diabetes Research and leader of international consortia, he bridges translational research and infrastructure development. His work involves: Establishing the German Mouse Clinic for systemic disease modeling Identifying 51 novel genes linked to metabolic diseases Advancing MALDI mass spectrometry imaging techniques Investigating progeria treatments and neurodevelopmental syndromes

Mamta Amruteمشاهده پروفایل

دانشیار

• Molecular motor proteins
• Hypertrophic cardiomyopathy
• Single molecule biophysics
• +۵ مورد دیگر

Dr. Mamta Amrute is an Associate Professor and Principal Investigator at the Institute of Molecular and Cell Physiology, Hannover Medical School (MHH), where she has led her research group since 2017. Her academic journey includes a PhD from MHH (2003-2006), postdoctoral research at MHH (2012-2016), and at the prestigious Medical Research Council-Laboratory of Molecular Biology in Cambridge, UK (2008-2011). Her research program focuses on single-molecule biophysics of molecular motor proteins , with particular emphasis on understanding how mutations in cardiac myosin lead to hypertrophic cardiomyopathy (HCM), a condition affecting approximately 1 in 200 individuals worldwide. The lab employs advanced techniques including Total Internal Reflection Fluorescence Microscopy, optical trapping, and zero-mode waveguides to investigate fundamental motor protein mechanisms. Analysis of recent publications reveals three major research trajectories: 1) Detailed characterization of cardiac and skeletal myosin isoforms at the single-molecule level, 2) Investigation of epigenetic regulation in muscle physiology and atrophy, and 3) Development of computational tools for biochemical research. This work has significant implications for understanding and potentially treating heart disease and muscle wasting conditions. Dr. Amrute's research is supported by multiple funding sources including the Deutsche Forschungsgemeinschaft (DFG), Fritz Thyssen Foundation, and MHH's early career research grant program (HilF). She supervises a diverse team of doctoral students and postdoctoral researchers, providing training in advanced biophysical techniques. The Amrute-Nayak Research Group maintains an extensive international collaboration network spanning institutions in the UK, USA, Japan, Italy, Sweden, and Australia, facilitating cross-disciplinary approaches to studying molecular motors and muscle diseases. Her work bridges fundamental biophysics with clinical applications in cardiology and muscle physiology.

Gianni Panagiotouمشاهده پروفایل

استاد

• Microbiome Dynamics
• Systems Biology
• Infectious Diseases
• +۵ مورد دیگر

Prof. Dr. Gianni Panagiotou heads the Department of Microbiome Dynamics at Leibniz Institute for Natural Product Research and Infection Biology and holds a professorship at Friedrich Schiller University Jena. His research integrates meta-omics and eco-systems biology to investigate host-microbiome interactions in metabolic diseases, infections, and sepsis. Research focuses include: Microbiome dynamics in health/disease states Systems biology of infectious pathogens Personalized nutrition strategies Gut-lung axis dysbiosis mechanisms Machine learning for microbiome diagnostics Recent publications demonstrate strong emphasis on clinical translation, with 2025 studies in Nature Medicine , Cell Reports , and mBio revealing microbiome signatures for NAFLD, fungal-pathogen interactions in lungs, and sepsis bioenergetics. The lab employs germ-free models and multi-omics integration to advance precision medicine. He leads the EU consortium 'MiCCrobioTAckle' exploring gut microbiome roles in cancer cachexia and teaches advanced courses in microbiome systems biology. His group maintains active collaborations across 15+ countries.

Stephan von Haehlingمشاهده پروفایل

استاد

• Heart Failure
• Metabolic Cardiology
• Cardio-Oncology
• +۳ مورد دیگر

Stephan von Haehling is DZHK Professor of Metabolic Cardiology at the University of Göttingen's Faculty of Medicine and Heart Center Göttingen. He serves as spokesperson for the German Society of Cardiology's Heart Failure Working Group and deputy editor of ESC Heart Failure , focusing on clinically relevant heart failure and cardio-oncology research. His primary research examines comorbidities in heart failure, particularly sarcopenia (affecting over 20% of patients) and bone metabolism deterioration. His team demonstrated sarcopenia's role as an independent mortality predictor, leading to its inclusion in European Society of Cardiology guidelines. In cardio-oncology, they investigate cancer-induced cardiovascular changes that impair physical resilience and quality of life, identifying biomarkers like osteoprotegerin and kynurenine for early prediction. Recent publications (2020-2023) emphasize heart failure management during the COVID-19 pandemic, cardio-oncology quality-of-life metrics, bone health in heart failure, and diagnostic biomarkers for acute heart failure. His work combines clinical trials, retrospective analyses, and biomarker validation, significantly influencing European treatment guidelines. Prof. von Haehling leads a research team at Göttingen's Heart Center, conducting translational studies on metabolic cardiology with international collaborations through the German Centre for Cardiovascular Research (DZHK).